Sera Prognostics (NASDAQ:SERA) CEO Sells $43,014.10 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 22,639 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $1.90, for a total value of $43,014.10. Following the completion of the transaction, the chief executive officer owned 741,287 shares of the company’s stock, valued at $1,408,445.30. This trade represents a 2.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Zhenya Lindgardt also recently made the following trade(s):

• On Wednesday, March 11th, Zhenya Lindgardt sold 2,973 shares of Sera Prognostics stock. The stock was sold at an average price of $2.04, for a total value of $6,064.92.

Sera Prognostics Price Performance

NASDAQ SERA traded up $0.06 during trading hours on Thursday, hitting $1.99. The company had a trading volume of 114,100 shares, compared to its average volume of 65,142. The company has a market capitalization of $76.80 million, a price-to-earnings ratio of -2.58 and a beta of 1.01. The firm’s 50 day moving average is $2.76 and its 200 day moving average is $3.05. Sera Prognostics, Inc. has a fifty-two week low of $1.37 and a fifty-two week high of $4.24.

Institutional Investors Weigh In On Sera Prognostics

Large investors have recently bought and sold shares of the company. Captrust Financial Advisors grew its holdings in shares of Sera Prognostics by 20.0% during the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after purchasing an additional 100,366 shares during the last quarter. Balentine LLC acquired a new stake in shares of Sera Prognostics in the 3rd quarter valued at about $258,000. Jane Street Group LLC acquired a new position in Sera Prognostics during the fourth quarter worth $203,000. Vanguard Group Inc. lifted its position in Sera Prognostics by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock valued at $3,725,000 after acquiring an additional 54,008 shares in the last quarter. Finally, Aberdeen Group plc boosted its position in shares of Sera Prognostics by 2.3% during the third quarter. Aberdeen Group plc now owns 2,279,699 shares of the company’s stock valued at $6,976,000 after buying an additional 52,332 shares during the last quarter. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Key Sera Prognostics News

Here are the key news stories impacting Sera Prognostics this week:

• Neutral Sentiment: Sera is scheduled to report quarterly earnings next week; investors will focus on revenue, cash runway and any guidance or clinical/commercial updates. Sera Prognostics (SERA) to Release Earnings on Wednesday
• Negative Sentiment: Several insiders sold shares on March 10–11 (CEO Zhenya Lindgardt, CFO Austin Aerts, General Counsel Benjamin Jackson and other officers). Sales were executed around $1.90–$2.04 and, while each sale reduced positions by under ~3%, the collective insider selling totaled tens of thousands of dollars and may be viewed negatively by the market. Filings for these transactions are available with the SEC. SEC Filing (example: CEO disclosures)

Analysts Set New Price Targets

Several analysts recently commented on SERA shares. Jefferies Financial Group upgraded shares of Sera Prognostics to a “strong-buy” rating in a report on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sera Prognostics in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.00.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.